Meeting
2020 Genitourinary Cancers Symposium
A pilot study of docetaxel and carboplatin for treatment of patients with mCRPC containing biallelic inactivation of genes in the BRCA1/2 pathway.
Authors
Heather H. Cheng
University of Washington, Seattle, WA
Heather H. Cheng , Makayla DeJong , Evan Y. Yu , Roman Gulati , Matthew Rettig , Celestia S. Higano , Peter Nelson , Colin C. Pritchard , Robert B. Montgomery
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02598895
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 127)
Abstract #
127
Poster Bd #
F7
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Final results of a pilot study of docetaxel and carboplatin for treatment of patients with mCRPC containing biallelic inactivation of genes in the homologous recombination DNA repair pathway.
First Author: Ruben Raychaudhuri
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world effectiveness of PARP inhibitors (PARPi) in metastatic castration-resistant prostate cancer (mCRPC) by genomic homologous recombination repair (HRR) alterations and homologous recombination deficiency signature (HRDsig).
First Author: Daniel Triner
Poster
2022 ASCO Genitourinary Cancers Symposium
Differential efficacy of PARP inhibitors in metastatic castration-resistant prostate cancer with DNA repair defects: A systematic review and meta-analysis.
First Author: Syed Arsalan Ahmed Naqvi
Poster
2018 ASCO Annual Meeting
Treatment outcomes for patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) pts and DNA damage repair gene mutations.
First Author: Steven Yip